A Study of ZN-c3 in Participants With Solid Tumors
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2 open-label, multicenter study, evaluating the safety, tolerability,
efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN-c3 alone and in combination with
other drugs.